Wintergreen Advisers Llc decreased Altria Group Inc (MO) stake by 21.2% reported in 2016Q4 SEC filing. Wintergreen Advisers Llc sold 154,434 shares as Altria Group Inc (MO)’s stock declined 8.39%. The Wintergreen Advisers Llc holds 574,007 shares with $38.81M value, down from 728,441 last quarter. Altria Group Inc now has $138.09 billion valuation. The stock declined 0.40% or $0.29 reaching $71.42 per share. About 4.33M shares traded. Altria Group Inc (NYSE:MO) has risen 8.06% since August 31, 2016 and is uptrending. It has underperformed by 0.53% the S&P500.
The stock of Synergy Pharmaceuticals Inc (NASDAQ:SGYP) is a huge mover today! About 7.90 million shares traded or 19.52% up from the average. Synergy Pharmaceuticals Inc (NASDAQ:SGYP) has declined 13.53% since August 31, 2016 and is downtrending. It has underperformed by 22.12% the S&P500.The move comes after 6 months positive chart setup for the $899.87M company. It was reported on Apr, 7 by Barchart.com. We have $4.59 PT which if reached, will make NASDAQ:SGYP worth $62.99 million more.
Analysts await Altria Group Inc (NYSE:MO) to report earnings on April, 27. They expect $0.75 EPS, up 4.17% or $0.03 from last year’s $0.72 per share. MO’s profit will be $1.45 billion for 23.81 P/E if the $0.75 EPS becomes a reality. After $0.68 actual EPS reported by Altria Group Inc for the previous quarter, Wall Street now forecasts 10.29% EPS growth.
Investors sentiment increased to 0.99 in Q4 2016. Its up 0.12, from 0.87 in 2016Q3. It improved, as 54 investors sold MO shares while 525 reduced holdings. 135 funds opened positions while 440 raised stakes. 1.16 billion shares or 1.98% more from 1.14 billion shares in 2016Q3 were reported. Cadence Financial Bank Na owns 36,024 shares for 1.14% of their portfolio. Gideon Cap Advsrs Inc reported 0.31% of its portfolio in Altria Group Inc (NYSE:MO). Thompson Management owns 9,739 shares. Welch Group Ltd holds 0.06% of its portfolio in Altria Group Inc (NYSE:MO) for 4,171 shares. Moreover, Payden Rygel has 2.55% invested in Altria Group Inc (NYSE:MO). Senator Inv Gru Limited Partnership owns 4.10 million shares for 4.21% of their portfolio. Mariner Wealth Ltd Liability invested in 0.21% or 68,176 shares. Thompson Siegel & Walmsley Limited Com owns 16,898 shares. Indiana Mngmt owns 7,490 shares. 931 were reported by Shamrock Asset Management Lc. 8,845 are owned by Southeast Asset. Tradewinds Mngmt, a Washington-based fund reported 1,531 shares. Caisse De Depot Et Placement Du Quebec owns 443,824 shares or 0.08% of their US portfolio. Baring Asset reported 0.71% in Altria Group Inc (NYSE:MO). Cypress Asset Mngmt Tx reported 0.39% in Altria Group Inc (NYSE:MO).
Since October 31, 2016, it had 0 buys, and 1 insider sale for $1.05 million activity. Another trade for 15,960 shares valued at $1.05 million was sold by Barrington Martin J..
Among 15 analysts covering Altria Group Inc. (NYSE:MO), 8 have Buy rating, 1 Sell and 6 Hold. Therefore 53% are positive. Altria Group Inc. had 21 analyst reports since July 31, 2015 according to SRatingsIntel. The stock has “Outperform” rating by Credit Agricole on Thursday, July 30. The company was downgraded on Thursday, March 24 by Bank of America. CLSA maintained it with “Outperform” rating and $68 target in Thursday, September 15 report. The firm has “Sector Perform” rating by RBC Capital Markets given on Tuesday, November 3. The firm earned “Equal-Weight” rating on Tuesday, November 29 by Morgan Stanley. On Friday, October 30 the stock rating was downgraded by Cowen & Co to “Market Perform”. Stifel Nicolaus maintained Altria Group Inc (NYSE:MO) on Monday, June 27 with “Buy” rating. The stock has “Buy” rating by Bank of America on Wednesday, January 4. The stock of Altria Group Inc (NYSE:MO) earned “Hold” rating by Berenberg on Friday, February 3. The stock of Altria Group Inc (NYSE:MO) earned “Equal Weight” rating by Barclays Capital on Thursday, March 30.
Among 6 analysts covering Synergy Pharmaceuticals (NASDAQ:SGYP), 5 have Buy rating, 1 Sell and 0 Hold. Therefore 83% are positive. Synergy Pharmaceuticals had 12 analyst reports since August 25, 2015 according to SRatingsIntel. As per Thursday, October 29, the company rating was reinitiated by Roth Capital. The firm has “Buy” rating given on Monday, May 9 by Rodman & Renshaw. The firm earned “Buy” rating on Thursday, October 1 by H.C. Wainwright. The rating was maintained by Rodman & Renshaw on Monday, March 21 with “Buy”. The stock has “Outperform” rating by Oppenheimer on Thursday, January 5. The stock of Synergy Pharmaceuticals Inc (NASDAQ:SGYP) earned “Sell” rating by Citigroup on Thursday, April 6. The firm has “Buy” rating by Rodman & Renshaw given on Friday, January 20. As per Wednesday, March 16, the company rating was maintained by Citigroup. The company was downgraded on Friday, December 18 by Citigroup. The stock of Synergy Pharmaceuticals Inc (NASDAQ:SGYP) has “Buy” rating given on Friday, December 23 by Rodman & Renshaw.
Synergy Pharmaceuticals Inc. is a biopharmaceutical firm focused on the development and commercialization of gastrointestinal therapies. The company has market cap of $899.87 million. The Company’s product candidates include TRULANCE (plecanatide) and dolcanatide. It currently has negative earnings. The Firm is engaged in the discovery, research and development efforts around analogs of uroguanylin for the treatment of GI diseases and disorders.
Since November 4, 2016, it had 0 buys, and 1 sale for $593,936 activity. PAULSON & CO. INC. sold $593,936 worth of stock.
